Motivation: Exploring the potential curative effects of drugs is crucial for effective drug development. Previous studies have indicated that integration of multiple types of information could be conducive to discovering novel indications of drugs. However, how to efficiently identify the mechanism behind drug-disease associations while integrating data from different sources remains a challenging problem. Results: In this research, we present a novel method for indication prediction of both new drugs and approved drugs. This method is based on Laplacian regularized sparse subspace learning (LRSSL), which integrates drug chemical information, drug target domain information and target annotation information. Experimental results show that the proposed method outperforms several recent approaches for predicting drug-disease associations. Some drug therapeutic effects predicted by the method could be validated by database records or literatures. Moreover, with L1-norm constraint, important drug features have been extracted from multiple drug feature profiles. Case studies suggest that the extracted drug features could be beneficial to interpretation of the predicted results. Availability and Implementation: https://github.
Introduction
Development of a new drug for a disease is an expensive and protracted progress. The productivity of pharmaceutical R&D has been stagnating over the past decades (Paul et al., 2010) . Despite the increasing R&D investment and the progress in life science, the number of new drugs approved by major drug regulatory bodies around the world has been decreasing for years (Mathieu et al., 2006) . There is an urgent need for new strategies for reducing the time and cost of drug development.
Computational methods which predict indications for new drugs or associate approved drugs with novel indications can be helpful for more effective drug development (Hurle et al., 2013) . These methods employ different characteristics of drugs and diseases to discover novel associations between them. Dakshanamurthy et al. (2012) proposed a proteochemometric method which combined multiple chemical signatures to predict new indications of drugs. Using gene expression profiles of diseases and drugs, Sirota et al. (2011) developed a computational approach to uncover new therapeutic potential of approved drugs. Phenotypic information such as side effects of drugs was also utilized to identify novel drug-disease associations (Yang and Agarwal, 2011) . In addition, Chiang and Butte (2009) Original Paper on 'guilt by association' approach which exploited the known therapies of drugs.
With the accumulation of drug related data, lots of methods that integrate heterogeneous information to explore the potential uses of drugs are put forward. Gottlieb et al. (2011) integrated multiple drug-drug and disease-disease similarity metrics by a logistic regression model to predict novel drug-disease associations. PreDR took advantage of kernel based strategy to combine chemical structure, molecular activity and phenotypic data for drug repositioning (Wang et al., 2013) . Iwata et al. (2015) developed a statistical model for predicting drug indications by the integration of the phenotypic features of drugs and molecular features of diseases. By the construction of a triple-layer heterogeneous network with drug chemical similarity, target similarity and disease similarity, Wang et al. (2014b) formulated a computational framework (TL-HGBI) for drug repositioning. The integrative analysis methods can more efficiently explore multiple levels of drug information and usually promote the accuracy of drug indication prediction, but there are few methods that could identify important drug features for the indication prediction while integrating various sources of information. The interpretability of the model is very important for the task of drug-disease association prediction. First, as the prediction results are obtained by integration of multiple sources of high dimension information, an interpretable model will help domain experts to understand the predicted results by presenting the features which are used to get these results. It will also help to design experiments to confirm the results. Second, an interpretable model may be benefit for extraction of the treatment mechanism hidden in the drug-disease association data. However, the interpretability of the model is seldom considered by previously integrative methods for drug indication prediction.
In this work, we intend to provide a method which has both good performance and improved interpretability. For this purpose, we propose a novel computational approach named LRSSL for drug indication prediction and informative drug feature extraction. Inspired by the previously works (Kim and Park, 2007; Shi et al., 2015) , LRSSL is constructed according to the following steps. First, the therapeutic effects of drugs depend on the binding of the drugs to their targets and the accompanying function alteration of the targets. In accordance with this, multiple types of drug features, including drug chemical substructure, target protein domain and target gene ontology annotation are projected to a common subspace which keeps consistent with the original indication labels of drugs. Second, drugs with similar chemical structure, targets and known indications should be close to each other in the subspace. As a result, Laplacian regularization terms are incorporated in our model to satisfy the smoothness of the subspace. Third, as not all the drug features are related to their therapeutic effects, L 1 -norm constraint is employed for sparse feature selection. Finally, a joint model is formed and an optimization algorithm is developed to solve this model. We evaluate our method on a drug-disease dataset adopted from previous study (Wang et al., 2014a) and compare it with other drug indication prediction methods. The results demonstrate that the proposed method shows better performance than the baseline methods as well as the state-of-art methods. Some novel drug-disease associations predicted by LRSSL can be validated by database records or literatures. Furthermore, LRSSL has the capability to extract important drug features from different drug feature profiles. Case studies show that the extracted drug features could be helpful to interpret the underlying mechanisms of the predicted results.
Materials and methods

Dataset
We obtained the drug-target interaction data and drug-disease association data from a published work (Wang et al., 2014a) . FDAapproved small molecule drugs which have both target and therapeutic indication information are kept for this study. There are 763 drugs and 681 diseases in the dataset of our study. The chemical fingerprints defined in the PubChem database (Wang et al., 2009) were extracted to represent the chemical substructures of drugs. Protein domains of target proteins were obtained from InterPro database (Mitchell et al., 2015) . Gene ontology information (molecular function and biological process) of target proteins was obtained from UniProt database (UniProt Consortium, 2010) . Then, each target protein was represented by its protein domains and gene ontology terms. The side effect information of drugs was extracted from SIDER database (Kuhn et al., 2015 
where y(i) and y(j) are indication profiles of drug i and drug j. The similarity between y(i) and y(j) is the maximum semantic similarity between these two disease groups. Semantic similarity of diseases is calculated using method from previous study (Wang et al., 2010) .
The graph Laplacian matrix L p of drug feature graph S p is defined as:
where D p is a diagonal matrix with D p ði; iÞ ¼ P n j S p ði; jÞ. These graph models are used to introduce smooth regularization, as drugs with similar features should have similar therapeutic effects. The Laplacian matrix L Y of drug indication similarity graph S Y is defined in the same way. This graph model is used to reflect the correlation and similarity of the known indications between different drugs.
Formulation
The aim of this study is to predict the possible therapeutic effects of a new drug or reposition an approved drug to new indications using the three drug feature matrices. Meanwhile, drug features from the three feature profiles which may be important for the treatment of diseases are inferred to help us interpret the computational results.
To achieve the aims of this study, a model named LRSSL is developed. Firstly, in order to combine different kinds of drug features, all of the original drug feature profiles are projected to a common latent subspace. This could be expressed as the linear transformation of drug feature matrix:
where G p 2 R dpÂc is the projection matrix of the pth drug feature matrix. Then, the regression errors are minimized to learn the latent subspace:
In (5), jj Á jj F is the Frobenius norm. k is regularization parameter. m is the number of drug feature matrices and m ¼ 3 in this study. F 2 R nÂc represents the common space of drug features. G p ð:; jÞ is the jth column of G p . The second term in (5) is L 1 -norm, it is employed to impose sparsity on G p . Elements of G p describe the weights of drug features and are required to be non-negative for computational efficiency and easier comprehension. Secondly, for the purpose of drug indication prediction, the latent subspace F should be consistent with the known drug-disease associations Y:
On the other side, the underlying subspace should keep the local structure of the original drug feature space and retain the correlation and similarity relationships of the known drug indications, the objective function in (6) is reformulated as follows:
In (7), a Á is introduced to control the contribution of different graph Laplacian regularization matrices. The parameter c > 1 is used to ensure that all the graph models contribute to the drug indication prediction and facilitate comprehensive understanding of the results.
By Combining (5), (7) and let
where l is a parameter that balances different parts of the model. In (8), the original drug feature space is projected to a common latent subspace while the local and global structure consistency is preserved. L 1 -norm constraint term in the objective function makes the model extract informative features for indication prediction from multiple drug feature profiles simultaneously.
Optimization
We have developed an iterative method to optimize the above objection function (8). Initially, a Á is set to 1/4, G 1 , G 2 and G 3 are initialized with random non-negative values from uniform distribution on the interval [0,1] respectively. First, set the derivative of (8) respected to F to zero. We have:
and
Then, we update F as following:
After that, F is fixed, the objective function becomes the following problem:
In (13), e 1Âdp is a 1 Â d p vector with all values equal to 1. The Lagrangian function with respect to G p of (13) is:
where C is Lagrangian multiplier. Differentiating (14) with respect to G p :
Using the KKT condition, Cði; jÞG p ði; jÞ ¼ 0, we obtain:
and we update G p using the auxiliary function approach (Ding et al., 2010) :
where
In (17), the positive and negative parts of A are separated:
B þ and B -are defined as the same way.
Finally, we fix F and G p , and renew the value of a Á by following equation according to (Shi et al., 2015) :
By applying the above update formulas, the objective function (8) is solved and the parameters are determined by cross validation. The convergence proof of the optimization algorithm, the complexity analysis and the influence of the initiation of G p are included in the Supplementary Material.
Performance evaluation
The performance of our algorithm is tested under two kinds of settings:
• Therapeutic effect prediction of new drugs.
• Repositioning approved drugs to novel indications.
Under the first setting, the drugs in the dataset are divided into five subsets randomly, then 5-fold cross validation is carried out while all disease associations of the test drugs are removed. In the second setting, drugs with more than one indication records are picked out, and the disease associations of these drugs are randomly split into 10 subsets, then 10-fold cross validation is conducted. We compare our method with two base line methods: L 1 -regularized logistic regression (L1LOG) and linear SVM (L1SVM) as well as two stateof-art methods: TL-HGBI (Wang et al., 2014b) and PreDR (Wang et al., 2013) . Four evaluation metrics are used to compare the performance of different methods: the area under the ROC curve (AUC), mean average precision (MAP), half-life utility (HLU) (Breese et al., 1998) and Precision at top-20. MAP is used to evaluate the overall performance of ranking. HLU is the metric for estimating the possibility of choosing an item from a ranked list by a user. For HLU, the half-life parameter is set to 5. Implementation details of the compared methods could be found in the Supplementary Material.
Results
Experimental analysis
There are several parameters that may influence the performance of our algorithm. Firstly, the sensitivity of regularization parameters l and k were studied by conducting a grid search strategy. The range of l was set to f10 À3 ; 10 À2 ; 10 À1 ; 1; 10; 10 2 g. The range of k was set to f10 À3 ; 10 À2 ; 10 À1 ; 1; 10; 10 2 g. Then, cross validation was conducted and AUC scores were calculated to evaluate the influence of parameters l and k on our method. As Supplementary Figure S2 shows, our method is moderately sensitive to the values of l and k. Specially, we set l ¼ 0:01 and k ¼ 0:01 in our following experiments. Next, we examined the variation of AUC scores with the change of the parameter c's value. We found that as the value of c was increased, the AUC scores of the method were slightly decreased (as shown in Supplementary Fig. S3 ). It is also noted that the parameter c impacts the value of a Á , thus it could control the relative contribution of different feature profiles (as shown in Supplementary Fig.  S4 ). When c is very large, the value of a Á % 0:25, this means that all the original feature space contributes equally. In the rest part of this work, we set c ¼ 2 to get a good predication performance and keep information from all the original feature space. We also found that our method was not very sensitive to the number of the nearest neighbours k in the graph models ( Supplementary Fig. S3 ). The value of k was fixed as 10 in the following work.
The predictability of different drug feature profiles
There are three types of drug features in this work. To examine the predictability of each drug feature profile, we firstly verified the associations between each feature profile and drug therapeutic effects. It is noticed that the mean chemical structure similarity of drugs with indication similarity ! 0:5 is 0.5683, while the mean chemical structure similarity of drugs with indication similarity < 0.5 is 0.5162. The mean target domain similarity of drugs with indication similarity ! 0:5 is 0.1537, while the mean target domain similarity of drugs with indication similarity < 0.5 is 0.0426. The mean target annotation similarity of drugs with indication similarity ! 0:5 is 0.1828, while the mean target annotation similarity of drugs with indication similarity < 0.5 is 0.0711. All the differences are statistically significant (Wilcoxon rank-sum, P-value < 0.001). We also preliminarily explored the strength of the associations between each feature profile with drug indication profile by fitting linear models using drug feature similarity against drug indication similarity separately. We found all of the drug feature similarities are positively correlated with indication similarity, and the linear model using target annotation similarity has the biggest slope coefficient (Supplementary Fig. S5 ). Then we predicted drug indications with each single drug feature profile by LRSSL. It is observed that the target annotation features have the best predictability while chemical substructure features have the poorest prediction performance. We also used different kinds of chemical fingerprints to represent the drug chemical substructure, but the performance is not improved (Supplementary Table S1 ). In accordance with previous study (Wang et al., 2014b) , it is implied the target information is important for drug indication prediction.
Performance comparison with other methods
To evaluate the performance of the proposed method, we compared it with both baseline methods and state-of-art methods. L1LOG and L1SVM are two popular classifiers which combine L 1 -regularization with logist regression or SVM. For these two methods, we concatenated all three drug feature matrices into a single combined feature matrix. Then L1LOG and L1SVM models were trained using the combined feature matrix. Here, these two methods were used as baseline methods which didn't take the correlation and complementation of different drug features into consideration. PreDR (Wang et al., 2013) utilizes kernel fusion to integrate chemical similarity, target protein similarity, side effect similarity and disease similarity information of known drug-disease pairs, then SVM is trained to predict novel drug-disease associations. TL-HGBI constructs a triple-layer heterogeneous network which incorporates drug-target and drug-disease relations with similarity information between drugs, targets and diseases, then an iterative algorithm is used to estimate the strength of unknown drug-disease associations.
Firstly we compared our method with L1LOG, L1SVM, PreDR and TL-HGBI for the task of indication prediction of novel drugs. As PreDR needs drug side effect information additionally, the comparisons were carried out using all drugs for L1LOG, L1SVM and TL-HGBI while using only the drugs with side effect for all methods separately. We conducted 5-fold cross validation for 20 times with different random seeds and calculated the AUC, MAP, HLU, Precision at top-20 values. Table 1 shows the average values and stand deviations of the four evaluation metrics for these methods under above setting. The proposed method shows the best performance over all methods under both datasets. The average AUC values of our method are 0.9074 and 0.9084, which is 6.8% and 6.7% higher than the second best method L1LOG. It is indicated that the local smooth regularization in LRSSL may improve the indication prediction by capturing the structure of the original drug feature space. It is also noticed that the performance of LRSSL is better when integrating all drug feature profiles than using each single drug feature profile (Supplementary Table S1 ). It is implied that information integration could improve the prediction accuracy of LRSSL. L1SVM shows similar performance with PreDR, which is also based on SVM model. TL-HGBI has the lowest AUC values among all of the methods but have better MAP and HLU values than the SVM based methods.
PreDR and TL-HGBI are developed for drug repositioning. Therefore we also compared our method with these two methods for the task of drug repositioning. Average AUC, MAP, HLU and Precision at top-20 values were calculated over 20 repetitions of 10-fold cross validation. As shown in Table 2 , LRSSL still has the best performance. The second best method, TL-HGBI performs much better for the task of drug repositioning and the values of four metrics are close to LRSSL, although the difference is still statistically significant (for AUC scores, P-value < 0.05, using two tailed ttest). The AUC scores of PreDR is improved under this setting, but still worse than the other two methods. It is noticed that PreDR integrates different drug information by taking the maximum similarity metrics of different drug features. This strategy may not fully utilize the information from the multiple feature profiles. From the above results, it is demonstrated that our method is not only useful for predicting indication of novel drugs, but also helpful for drug repositioning.
Weighting drug features for indication prediction
The projection matrix G p of LRSSL weights drug features in the corresponding feature profile. With L 1 -norm constraint, we can use G p to extract highly weighted drug features which could be of importance to predict drug-disease associations. To explore the potential meanings of the weights in G p , we calculated the spearman's correlation coefficients between the feature weights in G p and the frequencies of disease related features extracted from CTD (refer to Supplementary Material for more details). It is noticed that the correlation coefficients between feature weights and frequencies of disease related features are significantly larger than the correlation coefficients between feature weights and frequencies of randomly selected features as well as the correlation coefficients between random weights and frequencies of disease related features ( Supplementary Fig. S6 ). It hints that LRSSL may help to identify the common features shared among the drugs which are related to the same disease. Next, we compared the feature selection capability of LRSSL with L1SVM and L1LOG. For L1SVM and L1LOG, weight matrices were constructed from the positive weights in the classifiers. For LRSSL, all three of G p were concatenated to form a single weight matrix. These weight matrices were column normalized. Then we set the values below different thresholds (0.01 for LRSSL and L1LOG, 0.06 for L1SVM) in the weight matrices of these methods to zeros respectively and made the total of remained weights account for 85% of the total of the original weights, which means they keep the most of the information in the original weight matrices. After that the matrices were visualized. In Figure 1 , the top panel shows the matrix of the relationships between drug features and diseases in the original dataset. If a disease is the indication of a drug, then the values in this matrix which are corresponding to all the features of the drug are set to 1. Obviously, there are lots of redundant drug features. As seen in Figure 1 , our method, as well as L1SVM and L1LOG could highly weight a small portion of drug features in the original dataset. It is observed that the number of highly weighted drug features in L1SVM is much smaller than the other two methods, while the number of highly weighted features in our method is the biggest. The best results are in bold faces.
It is noticed that the number of drug features from different feature profiles is not even. As shown in Table 3 , in the original dataset, the average numbers of chemical features and target annotation features per disease are much larger than the average number of target domain features. The numbers of features highly weighted by L1SVM and L1LOG are also unevenly distributed and the ratios of drug feature numbers of the three feature profiles are close to the ratios of the original dataset. On the other hand, the unevenness is not that obvious for our method ( Fig. 1 and Table 3) . Besides, the a values in LRSSL can be recognized as the weights for different drug feature profiles. When the algorithm had converged, the a values for the three drug feature profiles were 0:21; 0:30 and 0.31 respectively. As a result, LRSSL could not only identify importance drug features but also learn to weight different feature profiles. This may reduce the bias of the different datasets. We also examined the impact of the number of known drug-disease and drug-target associations on the performance of our method and no significant effect is found (Supplementary Fig. S7 ). It is implied that LRSSL could more efficiently integrate and utilize information from different sources.
3.5 Case study 3.5.1 Indication prediction of novel drugs After examining the performance of the proposed method by cross validation, we applied it to predict indications of the small molecule drugs which didn't have any therapeutic indication records in DrugBank. The structure and target information of these drugs was retrieved as previously described. The drug-disease associations were predicted by our method, while all approved drugs in the original dataset were used as training data. We found that some topranked predictions were recorded in other public databases such as CTD (Davis et al., 2014) or TTD (Zhu et al., 2011) . For detail information, please refer to the supplemental Supplementary Tables S2  and S3. Table 4 here shows the top 5 predictions for some novel drugs for conciseness. The drug-disease associations which have been curated in CTD are indicated by boldface. Additionally, some of these top-ranked predictions could be supported by literature evidence. For example, neutropenia is ranked number 4 for quercetin, while previous study shows that quercetin could prolong neutrophils' lifespan and modulate neutropenia caused by etoposide toxicity (Kapiszewska et al., 2007) . Shock is ranked number 1 for Aminoguanidine, while several studies show that aminoguanidine could reduce the damage of shock in animal model (Soliman, 2014 (Soliman, , 2013 Wu et al., 1995) . Huperzine A, which is effective for Alzheimer's disease as curated in CTD, is also reported to treat myasthenia gravis (ranked number 3) (Cheng et al., 1986) . Veliparib is predicted to treat tumours and lymphoma, which has been investigated in a clinical study (Kummar et al., 2012) . These encouraging instances further confirm that our method can successfully predict therapeutic effects of novel drugs.
Drug repositioning
Our method has the capability for drug repositioning. To reposition drugs to novel indications, all approved drugs in the original dataset were used as the training data. After the algorithm converged, the latent subspace matrix F is regarded as the new label matrix for the drugs in the training set. High F(i, j) value suggests high possibility of the association between drug i and disease j. Taking CTD as the reference, we found that 563 drugs had additional records of therapeutic effects which didn't appear in the training data. Among these drugs, 263 (46.7%) drugs have at least one CTD curated disease association ranked in the top 5 by our method, 332 (58.9%) drugs have CTD curated disease association ranked in the top 10. Some The best results are in bold faces. top-ranked predictions for drug repositioning could be found in Table 5 and Supplementary Table S4 . Some additional top-ranked drug-disease associations are confirmed by SIDER database (Supplementary Table S5 ). There are also some drug-disease associations which are top-ranked while not recorded in CTD but can be proved by literatures. For example, the anti-depression effect of dextromethorphan has already been studied in a clinical trail (ClinicalTrials.gov, 2013) . Tacrolimus is an approved drug that is used for preventing transplantation rejection, but it is also found that this drug has potential to inhibits the growth of breast cancer (Siamakpour-Reihani et al., 2011) .
3.5.3 Interpretation of predicted drug-disease associations LRSSL can extract important drug features for the prediction of drug-disease associations. Here, we take ulcerative colitis as an example to illustrate how extracted features help to interpret the predicted drug-disease associations. Firstly, using LRSSL, top 10 ranked drugs which didn't have any indication records in DrugBank and top 10 ranked approved drugs for ulcerative colitis were selected. Secondly, 19 chemical substructure features, 29 target domain features and 31 target annotation features related to ulcerative colitis were selected by a weight threshold (>0.001). Thirdly, 6 drugs known for ulcerative colitis were picked. After that, a network was constructed by connecting the drugs and their features. The disease was connected to all the features. The whole network is visualized by Cytoscape (Shannon, 2003) in Fig. 2A . In this network, it is seen that all the predicted drugs share some highly weighted features with the known drugs for ulcerative colitis. Minocycline, which is for treatment of infections, has the most common features with sulfasalazine and balsalazide (Fig. 2B) . All of them target Arachidonate 5-lipoxygenase. The lipid metabolism and inflammation related protein domains and gene ontology terms shared by these three drugs mainly come from this target. It is implied that minocycline may have effects on ulcerative colitis through the regulation of inflammatory processes. This is proved by an experimental study (Garrido-Mesa et al., 2011) . In another example, lithium has the most common features with sulfasalazine and mesalamine, but has no common chemical substructure or target with both of these two drugs. A recent study demonstrates that lithium could stimulate the regeneration of colonic epithelium in colitis by inhibition of GSK3b (Raup-Konsavage et al., 2015) . This is in accordance with the protein domain IPR008271 (Serine/threonine-protein kinase, active site) and the gene ontology term GO:0042127 (regulation of cell proliferation) related to lithium (Fig. 2C) . The chemical compound hyperforine (CID:3662) is a polyphenol derivative. The features related to hyperforine such as IPR029580 (Prostaglandin G/H synthase 1) and GO:0002540 (leukotriene production involved in The predicted therapeutic effects which are confirmed by CTD records are in boldface. inflammatory response) suggest that this compound may exert influence on colitis through anti-inflammatory effect (Fig. 2D) . Therefore, the features extracted by our method could facilitate the interpretation of the prediction results.
Discussion
In this article, we present an integrative computational method based on Laplacian regularized sparse subspace learning (LRSSL). The proposed method is intended to predict novel drug-disease associations and identify important drug features from multiple feature profiles. An iterative algorithm is employed to optimize the objective function of LRSSL. The experimental results show that LRSSL outperforms other methods for drug indication prediction. Many predictions of LRSSL could be confirmed by database records or literatures which are unknown to the method. Moreover, LRSSL can extract drug features from different types of feature profiles. The case study indicates that the selected drug features are related to drug therapeutic effects and make the prediction results interpretable. The proposed method performs better than other methods in the task of indication prediction of new drugs. Different from similarity based methods, LRSSL associates a new drug to a disease by L1 regularized regression model, which improves the interpretability of the method. On the other hand, LRSSL weights individual features as well as different feature profiles, while L1LOG and L1SVM only give weights to drug features but ignore the difference between feature profiles. Compared to the work (Shi et al., 2015) , LRSSL exploits separate projected matrix for each feature profile to find the most relevant features from all profiles simultaneously. Meanwhile, LRSSL not only incorporates graph Laplacian regularization to keep local structure of different feature spaces but also capture the inter-relationships of drug indications. It is suggested that LRSSL could more effectively utilize complementary information from multiple sources. Furthermore, instead of directly using target proteins as the features of drugs, we use target protein domain and annotation information here. As seen in the case study, this increases the flexibility of our method for drug indication prediction and enables us to discover the potential mechanism of the drug curative effects.
Finally, there are some limitations of this work. When the number of diseases in the model becomes larger, the feature matrix whose dimension is smaller than the disease number is not necessarily projected to lower dimensional space. The drug-diseases associations may become more sparse and impair the prediction performance. Under this situation, it should be necessary to combine the disease terms according to the semantic similarity or the co-occurrence relationships of disease terms. On the other side, when the number of diseases is too small, the regularization of disease similarity may become invalid. Furthermore, the original data contains many irrelevant features. For example, some domains of drug targets may not participate in the binding or function of drugs. This may be improved by filtering the features with some prior knowledge beforehand. There is also a lot of drug and disease information such as gene expression and side effect which is not used in this study and the similarity between drugs and diseases could be calculated by various ways. For instance, it is possible to take the topological structure of ontology terms into consideration when calculating the the similarity of target annotations. Our method could be easily extended to include more feature profiles and similarity metrics. Finally, although the disease semantic similarity information is utilized to improve the performance (Supplementary Table S1 ), the method is mainly based on drug features. In future study, we plan to further develop our method to more efficiently exploit disease related features.
